Preliminary experience with diffuse correlation spectroscopy in acute ischemic stroke neurointerventional procedures.
Blood Flow
Laser
Stroke
Journal
Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
received:
05
04
2023
accepted:
03
05
2023
pmc-release:
17
11
2024
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
aheadofprint
Résumé
Diffuse correlation spectroscopy (DCS) is a non-invasive optical technique that enables continuous blood flow measurements in various organs, including the brain. DCS quantitatively measures blood flow from temporal fluctuations in the intensity of diffusely reflected light caused by the dynamic scattering of light from moving red blood cells within the tissue. We performed bilateral cerebral blood flow (CBF) measurements using a custom DCS device in patients undergoing neuroendovascular interventions for acute ischemic stroke. Experimental, clinical, and imaging data were collected in a prospective manner. The device was successfully applied in nine subjects. There were no safety concerns or interference with the standard angiography suite or intensive care unit workflow. Six cases were selected for final analysis and interpretation. DCS measurements with photon count rates greater than 30 KHz had sufficient signal-to-noise to resolve blood flow pulsatility. We found an association between angiographic changes in cerebral reperfusion (partial or complete reperfusion established in stroke thrombectomy cases; temporary flow arrest during carotid artery stenting) and those observed intraprocedurally with CBF measurements via DCS. Limitations of the current technology included sensitivity to the interrogated tissue volume under the probe and the effect of local changes in tissue optical properties on the accuracy of CBF estimates. Our initial experience with DCS in neurointerventional procedures showed the feasibility of this non-invasive approach in providing continuous measurement of regional CBF brain tissue properties.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse correlation spectroscopy (DCS) is a non-invasive optical technique that enables continuous blood flow measurements in various organs, including the brain. DCS quantitatively measures blood flow from temporal fluctuations in the intensity of diffusely reflected light caused by the dynamic scattering of light from moving red blood cells within the tissue.
METHODS
METHODS
We performed bilateral cerebral blood flow (CBF) measurements using a custom DCS device in patients undergoing neuroendovascular interventions for acute ischemic stroke. Experimental, clinical, and imaging data were collected in a prospective manner.
RESULTS
RESULTS
The device was successfully applied in nine subjects. There were no safety concerns or interference with the standard angiography suite or intensive care unit workflow. Six cases were selected for final analysis and interpretation. DCS measurements with photon count rates greater than 30 KHz had sufficient signal-to-noise to resolve blood flow pulsatility. We found an association between angiographic changes in cerebral reperfusion (partial or complete reperfusion established in stroke thrombectomy cases; temporary flow arrest during carotid artery stenting) and those observed intraprocedurally with CBF measurements via DCS. Limitations of the current technology included sensitivity to the interrogated tissue volume under the probe and the effect of local changes in tissue optical properties on the accuracy of CBF estimates.
CONCLUSION
CONCLUSIONS
Our initial experience with DCS in neurointerventional procedures showed the feasibility of this non-invasive approach in providing continuous measurement of regional CBF brain tissue properties.
Identifiants
pubmed: 37197931
pii: jnis-2023-020407
doi: 10.1136/jnis-2023-020407
pmc: PMC10654255
mid: NIHMS1928371
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : R21 NS130495
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MM: grant: NIH; consultant: Cerenovus, Medtronic; stock options: Bendit Technologies, Borvo Medical, BrainQ, Endostream, Serenity Medical, Synchron, Sim&Cure, QAS.AI, Quantanosis.AI; Assistant Editor for JNIS. WSB: grant: Athersys, BMS, Florida High Tech Corridor, NIH, Reneuron, VuEssence; consultant: Genentech, VuEssence; stock options: VuEssence; other: PRIME Education. ABP: grant: NIH; stock options: SPKL LLC.
Références
Neurophotonics. 2015 Jul;2(3):035004
pubmed: 26301255
Neurocrit Care. 2019 Feb;30(1):72-80
pubmed: 30030667
J Neurosurg. 1995 Sep;83(3):438-44
pubmed: 7666220
Stroke. 1997 Aug;28(8):1595-600
pubmed: 9259755
JTCVS Tech. 2021 Jan 29;7:161-177
pubmed: 34318236
Biomed Opt Express. 2011 Jul 1;2(7):1969-85
pubmed: 21750773
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012
Crit Care Med. 1991 Jan;19(1):89-97
pubmed: 1986896
Neurology. 1970 May;20(5):476-8
pubmed: 5462239
Neurocrit Care. 2010 Apr;12(2):173-80
pubmed: 19908166
J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1483-1494
pubmed: 30975462
Brain Sci. 2022 Aug 02;12(8):
pubmed: 36009088
N Engl J Med. 1991 Aug 15;325(7):445-53
pubmed: 1852179
Stroke. 2005 Sep;36(9):e83-99
pubmed: 16100027
Front Neurol. 2023 Mar 17;14:1052232
pubmed: 37006474
Neuroimage. 2014 Jan 15;85 Pt 1:51-63
pubmed: 23770408
Biomed Opt Express. 2016 Feb 03;7(3):776-97
pubmed: 27231588
Semin Neurol. 2012 Sep;32(4):454-65
pubmed: 23361488